XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
R
R

Roche

News

Reuters - 4 hours ago

Japan's Nikkei rises as chip-related shares track Nvidia higher

Japan's Nikkei rises as chip-related shares track Nvidia higher TOKYO, Nov 22 (Reuters) - Japan's Nikkei share average rose on Friday after two straight sessions of falls, as chip-related stocks tracked artificial intelligence darling Nvidia higher. The Nikkei .N225 had gained 1.02% to 38,415.32 by the midday break, but was set to fall 1.6% for the week.
N
R
J
U
U
Reuters - 3 days ago

Swiss trade surplus at CHF 8.063 bln in October

TABLE-Swiss trade surplus at CHF 8.063 bln in October November 19 (Reuters) - Switzerland ran a merchandise trade surplus of 8 .063 billion Swiss francs in October, the Federal Customs Office said on Tuesday. KEY FIGURES (millions of Swiss francs) October 2024 September 2024 Imports 19.681 17.620 Exports 27.745 22.562 Balance 8.063 4.942 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S
Reuters - 4 days ago

Japan's Nikkei tracks Wall Street losses; BOJ coy on hike timing

Japan's Nikkei tracks Wall Street losses; BOJ coy on hike timing Updates with closing prices By Kevin Buckland TOKYO, Nov 18 (Reuters) - Japan's Nikkei share average fell on Monday, taking cues from losses on Wall Street at the end of last week, after Bank of Japan chief Kazuo Ueda failed to offer strong hints on the timing of additional interest rate hikes.
N
R
U
J
Reuters - 4 days ago

Japan's Nikkei falls as tech shares track Wall Street losses

Japan's Nikkei falls as tech shares track Wall Street losses By Kevin Buckland TOKYO, Nov 18 (Reuters) - Japan's Nikkei share average fell on Monday as technology shares tracked U.S peers' losses at the end of last week, while drugmaker shares declined after a noted vaccine sceptic was appointed to head the U.S. Department of Health. Automaker shares came under pressure from an overall stronger yen, although the currency pulled back slightly from early highs after Bank of Japan Governor Kazuo Ue
N
R
U
J
Reuters - 1 week ago

Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job

UPDATE 7-Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job Vaccine skepticism concerns impact biotech investor sentiment Shares of European drug makers fall, along with U.S. companies Analysts worry about RFK Jr.'s influence on HHS agencies Updates throughout with detail on stock moves By Samuel Indyk and Ludwig Burger Nov 15 (Reuters) - Shares of major U.S.
A
G
M
P
P
R
S
C
K
C
Reuters - 1 week ago

European pharma stocks slip after Trump taps RFK Jr to lead top US health agency

BUZZ-European pharma stocks slip after Trump taps RFK Jr to lead top US health agency ** Share in healthcare companies drop the most in Europe, hurt by the news that Donald Trump has selected Robert F. Kennedy Jr. , who has previously spread misinformation on vaccines, to lead the country's top health agency ** STOXX 600 Healthcare index .SXDP at -2.09% is the biggest faller among the pan-European indices ** At 1113.76 points, the sub-index is at its lowest in 7 months and is heading for its big
A
G
R
S
U
Reuters - 2 weeks ago

Nykode Therapeutics To Regain Control Of VB10.Neo Program

BRIEF-Nykode Therapeutics To Regain Control Of VB10.Neo Program Nov 7 (Reuters) - Nykode Therapeutics ASA NYKD.OL : NYKODE THERAPEUTICS TO REGAIN CONTROL OF VB10.NEO PROGRAM NYKODE THERAPEUTICS ASA - IS NOT REQUIRED TO REFUND ANY UPFRONT PAYMENTS OR MAKE ANY FUTURE PAYMENTS TO GENENTECH ON TERMINATION NYKODE THERAPEUTICS ASA - EXISTING COLLABORATIO
R
Reuters - 3 weeks ago

Brainy efforts underway, but still some way to go for neuro drug developers

LIVE MARKETS-Brainy efforts underway, but still some way to go for neuro drug developers Main U.S. indexes sharply higher; Nasdaq, Dow up 1.3% Cons Disc leads S&P sector gainers; Utilities sole loser Euro STOXX 600 index up 1.3% Dollar rises; gold edges up; crude, up >1%, bitcoin up 0.4% U.S. 10-Year Treasury yield edges up to ~4.33% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
B
R
U
U
Reuters - 3 weeks ago

Regeneron shares drop as higher-dose Eylea drug misses sales estimates

UPDATE 1-Regeneron shares drop as higher-dose Eylea drug misses sales estimates Rewrites throughout to add details on higher dose version of Eylea By Christy Santhosh Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O o n Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease drug Eylea, sending its shares down 9%.
B
R
R
S
Reuters - 3 weeks ago

Regeneron beats results estimates on demand for eczema treatment, eye drug

Regeneron beats results estimates on demand for eczema treatment, eye drug Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea. Regeneron has been looking to upgrade patients who use Eylea to a high-dose version, as the drug that has long been its cash cow faces the threat of biosimilar products and stiff comp
B
R
R
S
Reuters - 3 weeks ago

Roche Presents New Data On Elecsys Amyloid Plasma Panel And Elecsys Ptau181

BRIEF-Roche Presents New Data On Elecsys Amyloid Plasma Panel And Elecsys Ptau181 Oct 31 (Reuters) - ROCHE HOLDING AG ROG.S : PRESENTS NEW DATA AT CTAD, DEMONSTRATING ITS GROWING MOMENTUM IN DIAGNOSTICS FOR ALZHEIMER'S DISEASE NEW DATA HIGHLIGHT POTENTIAL OF ROCHE ELECSYS® AMYLOID PLASMA PANEL AND ELECSYS PTAU181 FOR RULING OUT ALZHEIMER'S DISEASE
R
Reuters - 3 weeks ago

New England Journal Of Medicine Publishes Results For Roche's Itovebi, Showing More Than Doubling Of Progression-Free Survival In Certain Type Of Hr-Positive Advanced Breast Cancer

BRIEF-New England Journal Of Medicine Publishes Results For Roche's Itovebi, Showing More Than Doubling Of Progression-Free Survival In Certain Type Of Hr-Positive Advanced Breast Cancer Oct 31 (Reuters) - Roche Holding AG ROG.S : NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES LANDMARK PHASE III RESULTS FOR ROCHE’S ITOVEBI, SHOWING MORE THAN DOUBLING OF PROGRESSION-FREE SURVIVAL IN CERTAIN TYPE OF HR-POSITIVE ADVANCED BREAST CANCER U.S.
R
Reuters - 3 weeks ago

Nikkei closes at 2-week peak as tech shares track Nasdaq higher

Nikkei closes at 2-week peak as tech shares track Nasdaq higher Updates at 0600 GMT TOKYO, Oct 30 (Reuters) - Japan's Nikkei share average rose to a two-week closing high on Wednesday, as technology stocks tracked the Nasdaq's record finish overnight. The Nikkei .N225 climbed 0.96% to 39,277.39, its highest close since Oct. 15 in its third straight session of gains.
G
R
U
J
U
U
Reuters - 3 weeks ago

Japan's Nikkei hits two-week high as tech shares track Nasdaq's record high

Japan's Nikkei hits two-week high as tech shares track Nasdaq's record high TOKYO, Oct 30 (Reuters) - Japan's Nikkei share average touched a two-week high on Wednesday, as technology stocks tracked Nasdaq's record closing high overnight. The Nikkei .N225 was up 1.25% at 39,390.49 by the midday break, its highest level since Oct. 15. The broader Topix .TOPX rose 1.13% to 2,712.26. "There were not any strong market-moving cues and the momentum is not strong," said Fumio Matsumoto, chief strategist
G
N
R
U
J
U
U
Reuters - 4 weeks ago

NIH Says Bovine H5N1 Virus Is Susceptible To Antiviral Xofluza & Zanamivir

BRIEF-NIH Says Bovine H5N1 Virus Is Susceptible To Antiviral Xofluza & Zanamivir Oct 28 (Reuters) - NIH: NIH: BOVINE H5N1 INFLUENZA FROM INFECTED WORKER TRANSMISSIBLE AND LETHAL IN ANIMAL MODELS NIH: STUDY SHOWED BOVINE H5N1 VIRUS IS SUSCEPTIBLE TO ANTIVIRAL XOFLUZA AND NEURAMINIDASE INHIBITOR ZANAMIVIR NIH: STUDY SHOWED BOVINE H5N1 VIRUS IS LESS S
G
R
Reuters - 4 weeks ago

Assa Abloy, Kering, L'Oréal

EUROPE RESEARCH ROUNDUP-Assa Abloy, Kering, L'Oréal Oct 24 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Assa Abloy, Kering and L'Oréal, on Thursday. HIGHLIGHTS * Assa Abloy ASSAb.ST : Deutsche Bank raises target price to SEK 305 from SEK 300 * Barratt Redrow Plc BTRW.L : Morgan Stanley cuts target price to 580p from 600p * Dowlais Group Plc DWL.L : Citigroup raises to neutral from sell * Kering PRTP.PA : JP Morgan cuts target
B
D
D
D
E
E
H
H
K
K
L
L
P
R
R
R
S
S
S
S
S
T
Z
A
A
A
A
A
E
S
Reuters - 4 weeks ago

Roche comes out against allowing takeover of drug manufacturer Catalent

UPDATE 5-Roche comes out against allowing takeover of drug manufacturer Catalent Adds comment from Novo Holdings in paragraph 13 Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy groups also voice concerns over the deal Novo Nordisk and Catalent defend the acquisition, citing ample competition By Ludwig Burger FRANKFURT, Oct 23 (Reuters) - The CEO of p
A
A
P
R
Reuters - 4 weeks ago

Europe struggles for direction, earnings mixed

LIVE MARKETS-Europe struggles for direction, earnings mixed STOXX 600 flat Deutsche Bank, L'Oreal fall after earnings Wall St futures lower Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE STRUGGLES FOR DIRECTION, EARNINGS MIXED European equities are mixed on Wednesday, after several corporate reports, with markets remaining on edge as the U.S.
D
I
L
L
R
S
V
S
E
F
U
G
Reuters - 4 weeks ago

Roche CEO comes out against approving takeover of drug manufacturer Catalent

Roche CEO comes out against approving takeover of drug manufacturer Catalent FRANKFURT, Oct 23 (Reuters) - The CEO of Swiss pharmaceuticals giant Roche ROG.S said competition authorities should not allow the controlling shareholder of Novo Nordisk NOVOb.CO to acquiring contract drug manufacturer Catalent CTLT.N . "It's not a problem for us, but it could be a problem for other smaller players, if there is a restriction in how many (contract manufacturers) are available.
R
Reuters - 4 weeks ago

Europe before the bell: futures dip after raft of earnings

LIVE MARKETS-Europe before the bell: futures dip after raft of earnings Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE BEFORE THE BELL: FUTURES DIP AFTER RAFT OF EARNINGS European stock futures are edging lower in early trade after a large number of corporate earnings, with markets also watching rising yields and preparing for the upcoming U.S.
D
I
L
P
R
V
E
F
U
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.